Human health effects of conjugated linoleic acid from milk and supplements

Tracy A. McCrorie, Edel M. Keaveney, Julie M W Wallace, Nino Binns, B. Livingstone

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

The primary purpose of the present review was to determine if the scientific evidence available for potential human health benefits of conjugated linoleic acid (CLA) is sufficient to support health claims on foods based on milk naturally enriched with cis-9, trans-11-CLA (c9, t11-CLA). A search of the scientific literature was conducted and showed that almost all the promising research results that have emerged in relation to cancer, heart health, obesity, diabetes and bone health have been in animal models or in vitro. Most human intervention studies have utilised synthetic CLA supplements, usually a 50:50 blend of c9, t11-CLA and trans-10, cis-12-CLA (t10, c12-CLA). Of these studies, the only evidence that is broadly consistent is an effect on body fat and weight reduction. A previous review of the relevant studies found that 3.2g CLA/d resulted in a modest body fat loss in human subjects of about 0.09kg/week, but this effect was attributed to the t10, c12-CLA isomer. There is no evidence of a consistent benefit of c9, t11-CLA on any health conditions; and in fact both synthetic isomers, particularly t10, c12-CLA, have been suspected of having pro-diabetic effects in individuals who are already at risk of developing diabetes. Four published intervention studies using naturally enriched CLA products were identified; however, the results were inconclusive. This may be partly due to the differences in the concentration of CLA administered in animal and human studies. In conclusion, further substantiation of the scientific evidence relating to CLA and human health benefits are required before health claims can be confirmed.

Original languageEnglish
Pages (from-to)206-227
Number of pages22
JournalNutrition Research Reviews
Volume24
Issue number2
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Conjugated Linoleic Acids
Milk
Health
Insurance Benefits
Adipose Tissue
Literature
Heart Neoplasms
Weight Loss
Animal Models
Obesity
Body Weight
Bone and Bones
Food
Research

Keywords

  • Cis-9, trans-11-conjugated linoleic acid
  • Conjugated linoleic acid
  • Milk

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Human health effects of conjugated linoleic acid from milk and supplements. / McCrorie, Tracy A.; Keaveney, Edel M.; Wallace, Julie M W; Binns, Nino; Livingstone, B.

In: Nutrition Research Reviews, Vol. 24, No. 2, 12.2011, p. 206-227.

Research output: Contribution to journalReview article

McCrorie, Tracy A. ; Keaveney, Edel M. ; Wallace, Julie M W ; Binns, Nino ; Livingstone, B. / Human health effects of conjugated linoleic acid from milk and supplements. In: Nutrition Research Reviews. 2011 ; Vol. 24, No. 2. pp. 206-227.
@article{260ec443fcc84507a0a6acf615e330af,
title = "Human health effects of conjugated linoleic acid from milk and supplements",
abstract = "The primary purpose of the present review was to determine if the scientific evidence available for potential human health benefits of conjugated linoleic acid (CLA) is sufficient to support health claims on foods based on milk naturally enriched with cis-9, trans-11-CLA (c9, t11-CLA). A search of the scientific literature was conducted and showed that almost all the promising research results that have emerged in relation to cancer, heart health, obesity, diabetes and bone health have been in animal models or in vitro. Most human intervention studies have utilised synthetic CLA supplements, usually a 50:50 blend of c9, t11-CLA and trans-10, cis-12-CLA (t10, c12-CLA). Of these studies, the only evidence that is broadly consistent is an effect on body fat and weight reduction. A previous review of the relevant studies found that 3.2g CLA/d resulted in a modest body fat loss in human subjects of about 0.09kg/week, but this effect was attributed to the t10, c12-CLA isomer. There is no evidence of a consistent benefit of c9, t11-CLA on any health conditions; and in fact both synthetic isomers, particularly t10, c12-CLA, have been suspected of having pro-diabetic effects in individuals who are already at risk of developing diabetes. Four published intervention studies using naturally enriched CLA products were identified; however, the results were inconclusive. This may be partly due to the differences in the concentration of CLA administered in animal and human studies. In conclusion, further substantiation of the scientific evidence relating to CLA and human health benefits are required before health claims can be confirmed.",
keywords = "Cis-9, trans-11-conjugated linoleic acid, Conjugated linoleic acid, Milk",
author = "McCrorie, {Tracy A.} and Keaveney, {Edel M.} and Wallace, {Julie M W} and Nino Binns and B. Livingstone",
year = "2011",
month = "12",
doi = "10.1017/S0954422411000114",
language = "English",
volume = "24",
pages = "206--227",
journal = "Nutrition Research Reviews",
issn = "0954-4224",
publisher = "Cambridge University Press",
number = "2",

}

TY - JOUR

T1 - Human health effects of conjugated linoleic acid from milk and supplements

AU - McCrorie, Tracy A.

AU - Keaveney, Edel M.

AU - Wallace, Julie M W

AU - Binns, Nino

AU - Livingstone, B.

PY - 2011/12

Y1 - 2011/12

N2 - The primary purpose of the present review was to determine if the scientific evidence available for potential human health benefits of conjugated linoleic acid (CLA) is sufficient to support health claims on foods based on milk naturally enriched with cis-9, trans-11-CLA (c9, t11-CLA). A search of the scientific literature was conducted and showed that almost all the promising research results that have emerged in relation to cancer, heart health, obesity, diabetes and bone health have been in animal models or in vitro. Most human intervention studies have utilised synthetic CLA supplements, usually a 50:50 blend of c9, t11-CLA and trans-10, cis-12-CLA (t10, c12-CLA). Of these studies, the only evidence that is broadly consistent is an effect on body fat and weight reduction. A previous review of the relevant studies found that 3.2g CLA/d resulted in a modest body fat loss in human subjects of about 0.09kg/week, but this effect was attributed to the t10, c12-CLA isomer. There is no evidence of a consistent benefit of c9, t11-CLA on any health conditions; and in fact both synthetic isomers, particularly t10, c12-CLA, have been suspected of having pro-diabetic effects in individuals who are already at risk of developing diabetes. Four published intervention studies using naturally enriched CLA products were identified; however, the results were inconclusive. This may be partly due to the differences in the concentration of CLA administered in animal and human studies. In conclusion, further substantiation of the scientific evidence relating to CLA and human health benefits are required before health claims can be confirmed.

AB - The primary purpose of the present review was to determine if the scientific evidence available for potential human health benefits of conjugated linoleic acid (CLA) is sufficient to support health claims on foods based on milk naturally enriched with cis-9, trans-11-CLA (c9, t11-CLA). A search of the scientific literature was conducted and showed that almost all the promising research results that have emerged in relation to cancer, heart health, obesity, diabetes and bone health have been in animal models or in vitro. Most human intervention studies have utilised synthetic CLA supplements, usually a 50:50 blend of c9, t11-CLA and trans-10, cis-12-CLA (t10, c12-CLA). Of these studies, the only evidence that is broadly consistent is an effect on body fat and weight reduction. A previous review of the relevant studies found that 3.2g CLA/d resulted in a modest body fat loss in human subjects of about 0.09kg/week, but this effect was attributed to the t10, c12-CLA isomer. There is no evidence of a consistent benefit of c9, t11-CLA on any health conditions; and in fact both synthetic isomers, particularly t10, c12-CLA, have been suspected of having pro-diabetic effects in individuals who are already at risk of developing diabetes. Four published intervention studies using naturally enriched CLA products were identified; however, the results were inconclusive. This may be partly due to the differences in the concentration of CLA administered in animal and human studies. In conclusion, further substantiation of the scientific evidence relating to CLA and human health benefits are required before health claims can be confirmed.

KW - Cis-9, trans-11-conjugated linoleic acid

KW - Conjugated linoleic acid

KW - Milk

UR - http://www.scopus.com/inward/record.url?scp=84858809840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858809840&partnerID=8YFLogxK

U2 - 10.1017/S0954422411000114

DO - 10.1017/S0954422411000114

M3 - Review article

C2 - 22296934

AN - SCOPUS:84858809840

VL - 24

SP - 206

EP - 227

JO - Nutrition Research Reviews

JF - Nutrition Research Reviews

SN - 0954-4224

IS - 2

ER -